Better understanding of the different mutations that drive GIST is leading to new paradigms of tailored treatment that break many norms of chemotherapy, especially in management of progression. Download full article
Motzer and colleagues presented updated results from a multicentre, phase III trial of sunitinib versus interferon-á as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with [more]
Selected reports edited by Janet Fricker Download full article